Literature DB >> 25877354

Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.

Jun Tian1,2, Xiao-Juan Xu1, Lin Shen3, Yan-Ping Yang1, Rui Zhu1, Bo Shuai1, Xi-Wen Zhu1, Cheng-Gang Li1, Chen Ma1, Lin Lv1.   

Abstract

Wnt signaling plays an important role in the bone development and remodeling. The Wnt antagonist Dkk-1 is a potent inhibitor of bone formation. The aims of this study were firstly to compare the serum Dkk-1 levels in postmenopausal osteoporosis patients with age-matched healthy controls, and secondly, to assess the possible relationship between Dkk-1 and β-catenin, sclerostin, or bone turnover markers [CTX, PINP, N-MID-OT and 25(OH)D] in the setting of postmenopausal osteoporosis. A total of 350 patients with postmenopausal osteoporosis and 150 age-matched healthy controls were enrolled, and the serum levels of Dkk-1, β-catenin, sclerostin, OPG, and RANKL were detected by ELISA, and bone turnover markers [CTX, PINP, N-MID-OT and 25(OH)D] were measured by Roche electrochemiluminescence system in two groups. Serum Dkk-1 levels were significantly higher in postmenopausal osteoporosis group than in control group (P<0.001). Univariate analyses revealed that serum Dkk-1 levels were weakly negatively correlated to β-catenin (r=-0.161, P=0.003) and OPG (r=-0.106, P=0.047), while multiple regression analysis showed a negative correlation between serum Dkk-1 levels with β-catenin (β=-0.165, P=0.009) and BMD (β=-0.139, P=0.027), and a positive correlation between serum Dkk-1 levels and CTX (β=0.122, P=0.040) in postmenopausal osteoporosis group. No similar correlations ware observed in control group. The results provided evidence for the role of Dkk-1 in bone metabolism and demonstrated the link of Dkk-1 and Wnt/β-catenin in some ways.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25877354     DOI: 10.1007/s11596-015-1413-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  34 in total

1.  Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Authors:  Frederic Morvan; Kim Boulukos; Philippe Clément-Lacroix; Sergio Roman Roman; Isabelle Suc-Royer; Béatrice Vayssière; Patrick Ammann; Patrick Martin; Sonia Pinho; Philippe Pognonec; Patrick Mollat; Christof Niehrs; Roland Baron; Georges Rawadi
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

2.  Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.

Authors:  Feng-Sheng Wang; Jih-Yang Ko; Chun-Liang Lin; Hsing-Long Wu; Huei-Jin Ke; Pei-Ju Tai
Journal:  Bone       Date:  2006-10-20       Impact factor: 4.398

3.  Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.

Authors:  Ioannis Kyvernitakis; Tilman D Rachner; Anja Urbschat; Olaf Hars; Lorenz C Hofbauer; Peyman Hadji
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-07       Impact factor: 4.553

Review 4.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

5.  PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells.

Authors:  Akira Suzuki; Keiichi Ozono; Takuo Kubota; Hiroki Kondou; Kanako Tachikawa; Toshimi Michigami
Journal:  J Cell Biochem       Date:  2008-05-01       Impact factor: 4.429

6.  Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Charoula Xirakia; Konstantinos Varvagiannis; Georgios Boutsikas; Antonios Bilalis; Efstathios Kastritis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

7.  Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis.

Authors:  Emily Y Chu; Julie Hens; Thomas Andl; Alladin Kairo; Terry P Yamaguchi; Cathrin Brisken; Adam Glick; John J Wysolmerski; Sarah E Millar
Journal:  Development       Date:  2004-09-01       Impact factor: 6.868

Review 8.  The role of Dickkopf-1 in bone development, homeostasis, and disease.

Authors:  Joseph J Pinzone; Brett M Hall; Nanda K Thudi; Martin Vonau; Ya-Wei Qiang; Thomas J Rosol; John D Shaughnessy
Journal:  Blood       Date:  2008-08-07       Impact factor: 22.113

9.  The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow.

Authors:  Carl A Gregory; Harpreet Singh; Anthony S Perry; Darwin J Prockop
Journal:  J Biol Chem       Date:  2003-05-09       Impact factor: 5.157

10.  The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells.

Authors:  Oscar Aguilera; Cristina Peña; José Miguel García; María Jesús Larriba; Paloma Ordóñez-Morán; Diego Navarro; Antonio Barbáchano; Isabel López de Silanes; Esteban Ballestar; Mario F Fraga; Manel Esteller; Carlos Gamallo; Félix Bonilla; José Manuel González-Sancho; Alberto Muñoz
Journal:  Carcinogenesis       Date:  2007-04-21       Impact factor: 4.944

View more
  11 in total

1.  L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation.

Authors:  Shuwen Han; Xi Yang; Yuefen Pan; Quan Qi; Junjun Shen; Huifen Fang; Zhaoning Ji
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

2.  Activation of Wnt Signaling in Cortical Neurons Enhances Glucose Utilization through Glycolysis.

Authors:  Pedro Cisternas; Paulina Salazar; Carmen Silva-Álvarez; L Felipe Barros; Nibaldo C Inestrosa
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

3.  Serum sclerostin levels in osteoporotic fracture patients.

Authors:  Erwin A Gorter; Casper R Reinders; Pieta Krijnen; Natasha M Appelman-Dijkstra; Inger B Schipper
Journal:  Eur J Trauma Emerg Surg       Date:  2022-06-16       Impact factor: 3.693

4.  The Wnt pathway regulator expression levels and their relationship to bone metabolism in thoracolumbar osteoporotic vertebral compression fracture patients.

Authors:  Xuefeng Ma; Xiaoqi Zhu; Xu He; Xiaobo Yi; Anmin Jin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

5.  Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning.

Authors:  Bo Shuai; Lin Shen; Yanping Yang; Chen Ma; Rui Zhu; Xiaojuan Xu
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Systemic tracking of diagnostic function modules for post-menopausal osteoporosis in a differential co-expression network view.

Authors:  Chuan-En Wang; Jin-Qiang Wang; Yuan-Jian Luo
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

7.  Identification of serum β-catenin as a biomarker in patients with HBV-related liver diseases.

Authors:  Liang Duan; Qianfan Yang; Jun Yang; Qin Hu; Bo Wang; Pu Li; Weixian Chen
Journal:  J Transl Med       Date:  2018-09-29       Impact factor: 5.531

8.  Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis.

Authors:  Thor Ueland; Lis Stilgren; Jens Bollerslev
Journal:  Int J Mol Sci       Date:  2019-06-14       Impact factor: 5.923

Review 9.  Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Daniela Cici; Addolorata Corrado; Cinzia Rotondo; Francesco P Cantatore
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

10.  Assessment of Wnt pathway selected gene expression levels in peripheral blood mononuclear cells (PBMCs) of postmenopausal patients with low bone mass.

Authors:  Michal Stuss; Monika Migdalska-Sek; Ewa Brzezianska-Lasota; Marta Michalska-Kasiczak; Pawel Bazela; Ewa Sewerynek
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.